Immunome announced top‑line Phase III results showing its oral gamma‑secretase inhibitor produced an 84% reduction in the risk of disease progression or death versus placebo in progressing desmoid tumors. The magnitude of effect exceeded expectations for a rare‑tumor indication and prompted the company to say it will pursue a U.S. new drug application. The outcome underscores the value of targeted small molecules in rare soft‑tissue tumors and creates a near‑term regulatory milestone for Immunome.